Search: WFRF:(Mäkinen P)
> (2005-2009) >
PTFE bypass or thru...
PTFE bypass or thrupass for superficial femoral artery occlusion? : A randomised controlled trial
- Article/chapterEnglish2009
Publisher, publication year, extent ...
-
Elsevier BV,2009
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-110116
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-110116URI
-
https://doi.org/10.1016/j.ejvs.2009.01.003DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Early results of a thrupass endograft in the treatment of femoral lesions are promising. Less morbidity and better cost-effectiveness are suggested to be achieved in the treatment of chronic lower limb ischaemia with endovascular treatment compared to surgical treatment. PATIENTS AND METHODS: This randomised multicentre trial aimed to enroll a group of 60+60 patients for the treatment of 5-25-cm occlusions of superficial femoral artery (SFA) to be followed up for 3 years. Patients were treated either with endoluminal PTFE thrupass (WL Gore & Ass) or with surgical polytetrafluoroethylene (PTFE) bypass to proximal popliteal artery. Primary patency at 3 years was scheduled to be the primary end-point and secondary patency, functional success, costs and quality of life the secondary end-points. RESULTS: A sample of 100 consecutive SFA occlusions in one of the centres revealed that only 4% of the lesions were amenable for the study. The trial was prematurely terminated due to the results of an interim analysis at the time when 44 patients were recruited: the 1-year primary patency (excluding technical failures) was 48% for thrupass and 95% for bypass (p=0.02). The patency difference in favour of surgical bypass over endovascular thrupass was also sustained after completion of 1-year follow-up, the primary patencies being 46% and 84% at 1 year with grossly equilinear life-table curves thereafter (p=0.18), respectively. The corresponding secondary patencies were 63% and 100% (p=0.05) when excluding technical failures and 58% and 100% (p=0.02) according to intention-to-treat analysis. Secondary outcomes were thus not analysed. CONCLUSION: Treatment of SFA occlusions (TASC IIB and C or Imelda Ia and II) should be done by PTFE bypass rather than by PTFE thrupass, as thrupass is connected with worse early outcome. These results represent only a small category of femoral disease.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Laurila, K.
(author)
-
Roth, W-D.
(author)
-
Rossi, P.
(author)
-
Lavonen, J.
(author)
-
Mäkinen, K.
(author)
-
Manninen, H.
(author)
-
Romsi, P.
(author)
-
Perälä, J.
(author)
-
Bergqvist, DavidUppsala universitet,Kärlkirurgi(Swepub:uu)daviberg
(author)
-
Uppsala universitetKärlkirurgi
(creator_code:org_t)
Related titles
-
In:European Journal of Vascular and Endovascular Surgery: Elsevier BV37:5, s. 578-5841078-58841532-2165
Internet link
Find in a library
To the university's database
- By the author/editor
-
Lepäntalo, M.
-
Laurila, K.
-
Roth, W-D.
-
Rossi, P.
-
Lavonen, J.
-
Mäkinen, K.
-
show more...
-
Manninen, H.
-
Romsi, P.
-
Perälä, J.
-
Bergqvist, David
-
show less...
- Articles in the publication
-
European Journal ...
- By the university
-
Uppsala University